Publications by authors named "G H Beaton"
Article Synopsis
- People with Parkinson's disease often have speech problems, affecting how they talk and interact with others.
- The PD COMM trial tested two types of therapy to help with these speech issues: one is called Lee Silverman Voice Treatment LOUD, and the other is regular speech therapy from the National Health Service.
- The study took place in the UK and involved different groups of participants, comparing the effectiveness and cost of each therapy method against doing nothing.
Objectives: To assess the clinical effectiveness of two speech and language therapy approaches versus no speech and language therapy for dysarthria in people with Parkinson's disease.
Design: Pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
Setting: The speech and language therapy interventions were delivered in outpatient or home settings between 26 September 2016 and 16 March 2020.
Background: NASH causes a tremendous health care burden in the United States. A glucagon-like peptide-1 agonist, semaglutide (Sema), treatment resulted in hepatic steatosis reduction in clinical trials of NASH. Lysophosphatidic acid receptor 1 antagonists are known to have antifibrotic effects in several organs.
View Article and Find Full Text PDFDrug-eluting embolic transarterial chemoembolization (DEE-TACE) improves the overall survival of hepatocellular carcinoma (HCC), but the agents used are not tailored to HCC. Our patented liposomal formulation enables the loading and elution of targeted therapies onto DEEs. This study aimed to establish the safety, feasibility, and pharmacokinetics of sorafenib or regorafenib DEE-TACE in a VX2 model.
View Article and Find Full Text PDFBackground: Periprosthetic joint infection (PJI) and subsequent revision surgeries may affect patients' social and physical health, ability to complete daily activities, and disability status. This study sought to determine how PJI affects patients' quality of life through patient-reported outcome measures with minimum 1-year follow-up.
Methods: Patients who suffered PJI following primary total joint arthroplasty (TJA) from 2012 to 2021 were retrospectively reviewed.